Therapeutics: Glycogen synthase kinase 3 β (GSK3B); microtubule-associated protein τ (tau; MAPT; FTDP-17)

Neurology

INDICATION: Alzheimer's disease (AD)

In vitro and rodent studies identified an isonicotinamide-based GSK3β inhibitor that could help treat AD or other tauopathies.